Preface

Since the first in-man case was performed in 2002, transcatheter aortic valve implantation (TAVI) has been increasingly utilized, with rapid advancement in imaging and device technologies, implantation techniques and perioperative management. 30-day/in-hospital mortality and major complications of TAVI have dramatically decreased over this decade, and 5-year durability of transcatheter heart valves seems promising. TAVI has provided a new opportunity for curative treatment for inoperable or high-risk patients with severe aortic stenosis. Recent randomized controlled studies have shown excellent outcomes of TAVI in intermediate-risk patients and even in low-risk patients. The success of TAVI for aortic stenosis is likely to expand the indication of transcatheter therapy to aortic insufficiency, mitral and tricuspid valve diseases